Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Exelixis total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Exelixis's total debt was $189.12M at Dec 31, 2016. For fiscal 2016 it was $189.12M, down 54.7% from the year before. The highest annual figure on record is $417.94M in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $189.12M | -54.7% |
| FY2015 | Dec 31, 2015 | $417.94M | +17.1% |
| FY2014 | Dec 31, 2014 | $356.97M | +2.8% |
| FY2013 | Dec 31, 2013 | $347.24M | +3.4% |
| FY2012 | Dec 31, 2012 | $335.74M | +85.0% |
| FY2011 | Dec 31, 2011 | $181.52M | -12.9% |
| FY2010 | Dec 31, 2010 | $208.46M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2016 | Dec 31, 2016 | $189.12M | – |
See a number that looks wrong?